PureTech在ATS 2025上展示了Deupirfenidone的2b期数据，显示在统计学上显着放缓，在52周内具有持久效果，安全性状况良好，并计划在2025年底前召开FDA会议和启动3期试验

Deupirfenidone 825 mg TID slowed lung function decline in people with idiopathic pulmonary fibrosis (IPF) to the range expected of healthy older adults over 6 months; new, preliminary open-label extension data support durability of this treatment effect over at least 52 weeks

Deupirfenidone 825 mg TID demonstrated a statistically significant benefit compared to placebo in delaying IPF progression

Detailed safety analysis underscores favorable tolerability profile for deupirfenidone

PureTech plans to meet with FDA before end of Q3 2025, with the goal of initiating a Phase 3 trial by year-end

PureTech Health plc (NASDAQ:PRTC, LSE: PRTC))) ("PureTech" or the "Company"), a clinical-stage biotherapeutics company dedicated to changing the lives of patients with devastating diseases, delivered a late-breaking, oral presentation at the 2025 American Thoracic Society (ATS) International Conference in San Francisco. The presentation provided further insights into the successful Phase 2b ELEVATE IPF trial of deupirfenidone (LYT-100), highlighting the strength and durability of deupirfenidone's treatment effect through at least 52 weeks while maintaining favorable tolerability in patients living with idiopathic pulmonary fibrosis (IPF).